New Publication: Alzheimer‐related altered white matter microstructural integrity in Down syndrome: A model for sporadic AD?

Introduction

Virtually all adults with Down syndrome (DS) develop Alzheimer’s disease (AD)‐associated neuropathology by the age of 40, with risk for dementia increasing from the early 50s. White matter (WM) pathology has been reported in sporadic AD, including early demyelination, microglial activation, loss of oligodendrocytes and reactive astrocytes but has not been extensively studied in the at‐risk DS population.

Methods

Fifty‐six adults with DS (35 cognitively stable adults, 11 with mild cognitive impairment, 10 with dementia) underwent diffusion‐weighted magnetic resonance imaging (MRI), amyloid imaging, and had assessments of cognition and functional abilities using tasks appropriate for persons with intellectual disability.

Results

Early changes in late‐myelinating and relative sparing of early‐myelinating pathways, consistent with the retrogenesis model proposed for sporadic AD, were associated with AD‐related cognitive deficits and with regional amyloid deposition.

Discussion

Our findings suggest that quantification of WM changes in DS could provide a promising and clinically relevant biomarker for AD clinical onset and progression.

https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/dad2.12040

NIH Awards Over $100 Million to Examine Biomarkers of Alzheimer’s Disease in Adults with Down Syndrome

he Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS), a multi-institution research team, co-led by members from the University of California, Irvine, has been awarded an unprecedented five-year, $109 million grant by the National Institutes of Health (NIH), to expand research on the biomarkers of Alzheimer’s disease in adults with Down syndrome.

https://som.uci.edu/news_releases/ABC-DS-grant-awarded.asp?fbclid=IwAR3fuTF3dXAfjKezO3CaNtcEBbd31wIOPEdXRRKLYtbh8lJDwRPDeCHX7_o